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INTRODUCTION
Pancreatic cancer is the fifth most common cause of 
cancer-related deaths in South Korea, and the fourth 
leading cause of cancer-related deaths in the United States 
and Europe (1-4). Surgical resection is considered to be the 
only potentially curative treatment for pancreatic cancer. 
The majority of pancreatic cancer patients are diagnosed 
in locally advanced or metastatic status. Only 15% to 20% 
of pancreatic cancer patients are candidates for surgical 
resection (5). 
The role of imaging has been evolving in line with the 
development of pancreatic cancer treatment, and imaging 
plays a crucial role in the screening, diagnosis, preoperative 
staging, postoperative surveillance, and treatment response 
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evaluation of pancreatic cancer. This review focused on the 
latest treatment strategies for pancreatic cancer, as well as 
the role, limitations, and the future direction of imaging.
Current Treatment Strategy for Pancreatic 
Cancer
Pancreatic cancer is divided into four categories according 
to the local tumor extent and the presence of disseminated 
disease (Fig. 1). Treatment options vary for each category 
as follows (5-7):
1) Resectable: tumors with a high probability of margin-
negative resection 
2) Borderline resectable: tumors that are involved with 
nearby structures and are neither resectable nor clearly 
unresectable with a high chance of an positive microscopic 
margin (R1) resection
3) Locally advanced: tumors that are involved with nearby 
structures to an extent that renders them unresectable 
despite the absence of evidence of metastatic disease
4) Metastatic: tumors that have disseminated.
Margin-negative (R0) resection of localized pancreatic 
cancer is considered as the only potentially curative 
treatment. The 5-year survival rate is approximately 
18–24% when a R0 resection is achieved (8). R0 resection 
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combination chemotherapies are preferred in patients with 
good performance status (17, 18).
Localized pancreatic cancers with a low likelihood of R0 
resection can be divided into borderline resectable and 
locally advanced disease. Borderline resectable pancreatic 
cancer indicates tumors that are potentially downstaged 
and resectable upon favorable response to neoadjuvant 
therapy. Neoadjuvant therapy can increase the R0 resection 
rate in subsequent surgical resection, treat micrometastasis 
at an earlier stage, and provide an observation period to 
exclude pancreatic cancer showing rapid progression and 
poor response to therapy. Chemotherapy or chemoradiation 
therapies are more likely to be tolerated in the preoperative 
stage than in the postoperative stage (14, 19). Two 
meta-analyses illustrated that approximately one-third 
of the borderline resectable pancreatic cancers could be 
completely resected, and the 5-year survival rate of those 
cases was promising (> 20%) (20, 21). Chemotherapy with 
or without subsequent chemoradiation is commonly used in 
is defined by the absence of tumor cells within 1 mm 
of the surgical margin. Otherwise, the margin status is 
defined as a R1 or positive macroscopic margin (R2) (9, 
10). Patients categorized with either R1 or R2 margins in 
surgical resection show poor 5-year survival rates of 8–11%, 
similar to locally advanced disease (9, 11-14). Patients 
who are considered to have high probability of R0 resection 
in radiologic evaluation are classified as “resectable,” 
and may be candidates for upfront surgery. To improve 
the survival of R0 resection patients, various adjuvant 
chemotherapeutic or chemoradiotherapeutic regimens 
have been attempted. According to two recent clinical 
trials, patients treated with combination chemotherapies, 
including modified 5-FU/leucovorin, oxaliplatin, and 
irinotecan (FOLFIRINOX) or gemcitabine + capecitabine, 
showed significantly better overall survival than those 
treated with gemcitabine monotherapy (15, 16). In all of 
the patients who underwent upfront surgical resection, 
adjuvant therapy is recommended, and the abovementioned 
Fig. 1. Treatment strategy for pancreatic cancer. CT = computed tomography, EUS = endoscopic ultrasound, MRI = magnetic resonance 




















- MRI for indeterminate pancreatic or liver lesions
- PET/CT for patients at high risk of metastasis
- EUS for primary site evaluation
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neoadjuvant therapy (22). However, no specific regimen is 
recommended due to limited evidence (5). 
In unresectable pancreatic cancers, including locally 
advanced and metastatic disease, systemic chemotherapy 
is commonly employed. There are numerous options 
for a chemotherapeutic regimen. FOLFIRINOX/modified 
FOLFIRINOX, gemcitabine + nab-bound paclitaxel, and 
gemcitabine + cisplatin are the preferred regimens for 
patients with good performance status, while gemcitabine, 
capecitabine, and 5-FU monotherapy are the preferred 
regimens for patients with poor performance status. 
Chemoradiation or stereotactic body radiation therapy 
may be added for definitive treatment in locally advanced 
disease, and for palliative measures in metastatic disease.
Conventional Role of Imaging
Surveillance of Pancreatic Cancer
Surveillance is not recommended for asymptomatic 
general populations. In general populations, in which the 
incidence of pancreatic cancer is low (lifetime risk < 1.3%), 
the yield of surveillance is also low.
High-risk individuals (> 5% lifetime risk of pancreatic 
cancer) could be potential candidates for pancreatic cancer 
surveillance. High-risk individuals include 1) first-degree 
relatives (FDRs) of patients with pancreatic cancer from a 
familial pancreatic cancer kindred with at least two affected 
FDRs; 2) patients with Peutz-Jeghers syndrome; and 3) 
p16, BRCA2, and hereditary non-polyposis colorectal cancer 
mutation carriers with ≥ 1 affected FDRs (23). The detection 
of T1N0M0 pancreatic cancer that could be treated with R0 
resection and high-grade dysplastic lesions should be the 
goal of surveillance. As screening modalities, endoscopic 
ultrasound (EUS) and magnetic resonance imaging (MRI) 
are preferred. These imaging modalities have excellent 
sensitivity for small pancreatic lesions and do not use 
ionizing radiation. A few studies compared the diagnostic 
accuracy of EUS and MRI in a surveillance setting (24, 25), 
and showed that EUS is more accurate in the detection of 
small solid lesions (24). However, MRI is more sensitive 
in the detection of cystic lesions and main pancreatic 
duct communication, allowing the diagnosis of intraductal 
papillary mucinous neoplasm, which is considered to be a 
precancerous lesion (24, 26).
Imaging Diagnosis of Pancreatic Cancer
For imaging diagnosis of pancreatic cancer, diverse 
imaging modalities, including transabdominal ultrasound 
(US), computed tomography (CT), MRI and magnetic 
resonance cholangiopancreatography (MRCP), positron 
emission tomography (PET), and EUS are commonly 
used. The characteristics of these imaging modalities are 
summarized in Table 1.
Transabdominal Ultrasound
US is commonly used for initial imaging evaluation in 
asymptomatic or symptomatic patients. It is non-invasive, 
relatively inexpensive, and easily accessible. Pancreatic 
cancer often appears as a distinct or infiltrative hypoechoic 
focal pancreatic lesion, commonly accompanied by dilatation 
of the main pancreatic duct or bile duct. In conventional 
US, most focal pancreatic lesions exhibit hypoechogenicity; 
therefore, it is difficult to distinguish between pancreatic 
cancer and other focal pancreatic lesions. The diagnosis of 
pancreatic cancer in transabdominal US is highly dependent 
on the operator’s technique, patient’s body habitus, as well 
as the location and size of the tumor. The sensitivity and 
specificity of transabdominal US are considerably variable, 
ranging 68–95% and 50–100%, respectively (27-29). The 
limited diagnostic performance of US limits its role in 
the initial evaluation and lesion detection; therefore, US 
is rarely used for diagnosis, resectability evaluation, and 
response evaluation of pancreatic cancer.
Computed Tomography
CT shows excellent temporal and spatial resolution as 
well as wide anatomic coverage. It is recommended as 
the primary imaging modality for resectability evaluation 
according to the National Comprehensive Cancer Network 
(NCCN) and European Society for Medical Oncology (ESMO) 
guidelines (5, 7). The use of CT for treatment decision-
making should include a thin (preferably submillimeter) and 
continuous section and ≤ 3 mm reconstruction, multiplanar 
reformation including the coronal plane, and maximal 
intensity projection or three-dimensional (3D) volumetric 
thick section images for vascular evaluation. For a proper 
evaluation of pancreatic lesions and adjacent vascular 
structures, both the pancreatic phase (40–50 seconds from 
intravenous contrast injection) and venous phase (65–70 
seconds) should be included (6, 7). If the CT images do not 
conform to the pancreatic protocol, re-examination using 
a high-quality pancreatic protocol CT is recommended for 
precise evaluation of tumor staging (30). Since pancreatic 




echo dynamic images including precontrast, pancreatic, 
venous, and equilibrium phases; and T2-weighted MRCP 
sequences (7). The availability of various sequences 
and the superior soft-tissue contrast of MRI could assist 
in the detection and characterization of small, subtle, 
cystic, or isoattenuating pancreatic lesions and small 
liver lesions (Fig. 2). MRCP can non-invasively visualize 
abnormalities of the entire pancreatic and bile duct, 
including anatomic variations and obstructive dilatation. 
With these advantages, MRI is used as a problem-solving 
tool for indeterminate pancreatic lesions (especially 
small or isoattenuating tumors) or small liver lesions. 
MRI also shows some disadvantages, such as lower 
spatial resolution, vulnerability to motion artifacts, and 
limited multiplanar reformation capability. With its own 
advantages and disadvantages, MRI has shown similar 
diagnostic performance as CT. In meta-analyses, MRI has 
shown sensitivity of 84–93% and specificity of 82–89% 
for the diagnosis of pancreatic cancer (32-34, 40). In 
candidates for upfront surgery, MRI with DWI can detect 
hepatic metastasis in about 1.5–2.3% of patients with 
no hepatic lesions on CT, and about 10.5–13.6% of those 
with indeterminate liver lesions on CT (41). Particularly, 
MRI with hepatobiliary contrast using gadoxetic acid 
demonstrates higher sensitivity than CT (85% vs. 69%) and 
imaging evaluation should be performed within a month of 
definitive treatment (31). 
Pancreatic cancer is usually seen as a mass lesion that 
exhibits hypoenhancement compared to the adjacent 
parenchyma in the pancreatic phase. It may cause 
interruption and upstream dilatation of the pancreatic or 
bile duct, abutment or encasement of adjacent vascular 
structures, direct invasion of adjacent organs, and regional 
lymph node enlargement. In meta-analyses, CT has shown 
sensitivity of 89–91% and specificity of 85–90% for the 
diagnosis of pancreatic cancer (32-34). Liver, peritoneum, 
and distant lymph nodes are the most common metastatic 
sites. Approximately 5% of pancreatic cancer may exhibit 
isoattenuation in both the pancreatic parenchymal 
and venous phases (35, 36). In addition, CT shows low 
diagnostic accuracy for small liver, peritoneal, or lymph 
node metastasis (37-39).
Magnetic Resonance Imaging and Magnetic Resonance 
Cholangiopancreatography
MRI for pancreatic cancer evaluation is recommended to 
include the following sequences: T2-weighted fast spin-
echo; T1-weighted in-and-out of phase gradient-echo; T2-
weighted fat-suppressed fast spin-echo; diffusion weighted 
imaging (DWI); 3D T1-weighted fat-suppressed gradient-
Table 1. Characteristics of the Imaging Modalities Used for Diagnosis of Pancreatic Cancer
Imaging
Modalities
Strengths Weaknesses Diagnostic Role in Imaging
Diagnostic Performance 
for Diagnosis of 
Pancreas Cancer
US Accessibility
Sonographic window could be  
  limited; operator dependent
Initial assessment of  




High temporal and spatial  
   resolution; wide anatomic 
coverage
Inappropriate for surveillance  
   due to ionizing radiation; 
limited diagnostic performance 
in small pancreatic, hepatic, 
and peritoneal lesions
Primary imaging modality of 






Superior soft-tissue contrast;  
   visualization of pancreatic 
and biliary duct abnormality
Lower spatial resolution; 
  motion artifact
Adjunct diagnostic tool of  
   equivocal pancreatic lesion 




High spatial resolution; could  
   be coupled with fine needle 
aspiration biopsy
Invasive; operator dependent
Adjunct diagnostic tool of  





Majority of pancreas cancer  
   show increased 18FDG uptake; 
useful in evaluation of lymph 
node and distant metastasis 
Difficult to distinguish  
   between pancreatic cancer and 
pancreatitis
Evaluation of lymph node  
  and distant metastasis
Sensitivity 89–91%
Specificity 70–72%
CT = computed tomography, EUS = endoscopic ultrasound, MRI = magnetic resonance imaging, PET = positron emission tomography, US = 
ultrasound, 18FDG = 18fluorine-2-fluoro-2-deoxy-D-glucose
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higher accuracy for differentiating between metastasis and 
hepatic microabscess (37, 42). With increased sensitivity 
for liver metastasis, an additional MRI may change the 
results of resectability assessments in a significant number 
of patients (14.4%) (Fig. 3) (43). 
Pancreatic cancer shows hypointensity in precontrast T1-
weighted images. In T2-weighted images with or without 
fat suppression, the signal intensity of pancreatic cancer 
is variable (44). After contrast enhancement, the tumor 
usually shows hypoenhancement in the pancreatic phase, 
and occasionally delayed enhancement in the equilibrium 
phase. Since the majority of pancreatic cancers show 
restricted diffusion, DWI could help detect pancreatic 
cancer (45, 46). However, pancreatitis could appear as 
restricted diffusion, which is often indistinguishable from 
pancreatic cancer on DWI. In addition, DWI has poor spatial 
resolution and is vulnerable to artifacts caused by motion 
or bowel gas (47). Pancreatic cancer also often exhibits 
upstream pancreatic duct dilatation or cutoff on MRCP or 
T2-weighted imaging.
Positron Emission Tomography
18Fluorine-2-fluoro-2-deoxy-D-glucose (18FDG) is the 
most widely used radiotracer in PET scans. As a glucose 
analogue, 18FDG allows in vivo imaging of glycolytic 
activity, which is usually elevated in solid tumors, 
including pancreatic cancer. Both KRAS mutation, which 
is observed in most (> 90%) pancreatic cancers, and 
a hypoxic microenvironment increase 18FDG uptake by 
upregulating HK2 and GLUT1 expression. Since focal 
pancreatitis can also exhibit increased 18FDG uptake, it is 
difficult to distinguish between pancreatic cancer and focal 
pancreatitis (48). The potential additional benefits of 18FDG-
PET or 18FDG-PET/CT over pancreatic CT in the diagnosis 
of pancreatic cancer remain debatable (34, 49-51). 18FDG-
PET/CT shows a sensitivity of 89–91% and specificity of 
70–72% for diagnosis of pancreatic cancer (33, 34). PET/CT 
covers the entire body and is beneficial for finding distant 
metastases. It may also be useful in lymph node staging (51, 
52). The NCCN guidelines recommend that PET/CT should 
not be a substitute for pancreatic CT or MRI; however, it 
Fig. 2. Isoattenuating pancreatic cancer on CT. A 55-year-old female patient was referred for a small pancreatic lesion that was detected in 
transabdominal ultrasound (image was not available). 
Both pancreatic (A) and venous phases (B) in CT showed no demonstrable lesion in the pancreas or significant pancreatic duct dilatation. MRI 
showed an approximately 1.5-cm focal pancreatic lesion (white arrows) with hypointensity in the T1-weighted image (C), hypoenhancement in 
the pancreatic phase (D), and moderate hyperintensity in the T2-weighted image (E). Magnetic resonance cholangiopancreatography (F) showed 
minimal pancreatic duct dilatation distal to the pancreatic mass, suggesting duct involvement (white arrowheads). The mass was seen as a 







should not be delayed when clinical suspicion of pancreatic 
cancer is high (7). However, biopsy should be performed 
for patients with unresectable disease before initiating 
neoadjuvant or systemic chemotherapy with or without 
radiation. FNA using EUS is commonly performed for 
pathologic diagnosis. According to a recent meta-analysis, 
EUS-guided FNA has a sensitivity of 91% and specificity 
of 97% (56). Owing to the shorter penetration depth of 
EUS-guided FNA, in comparison with percutaneous CT or 
US-guided FNA, the diagnostic yield is similar, and the 
probability of postprocedural complications and peritoneal 
seeding is low (57, 58). Even in patients with resectable 
disease, FNA was not significantly associated with increased 
mortality, suggesting that FNA can be safely performed 
without having a significant impact on the patient’s 
clinical course (59). If EUS-guided FNA for a tumor is not 
possible, other methods such as brushing cytology with 
cholangiography, CT- or US-guided percutaneous biopsy, 
and laparoscopic biopsy could be performed as alternatives. 
Percutaneous biopsy is contraindicated in potentially 
resectable pancreatic cancer, due to the risk of tumor 
seeding (5).
Recently, the importance of genetic profiling of tumors 
has been gradually emphasized. In the recently updated 
NCCN guidelines, genetic profiling of tumor tissue was 
could be combined with CT or MRI as an adjunct modality 
in patients at high risk of metastatic disease, such as those 
with borderline resectable disease, markedly elevated CA19-
9 levels, large primary tumors, large regional lymph nodes, 
and a very symptomatic presentation (7).
Endoscopic Ultrasound
Because of its high spatial resolution, EUS can be used to 
obtain additional information for pancreatic cancers when 
the pancreatic lesion is equivocal in CT or when there is 
questionable blood vessel or lymph node involvement (53-
55). However, the operator dependence of EUS and anatomic 
variations of the celiac and superior mesenteric arteries can 
limit the diagnostic capability of EUS. EUS shows sensitivity 
of 89–91% and specificity of 81–86% for the diagnosis of 
pancreatic cancer (33, 34). However, the inclusion of EUS 
as a routine imaging tool for a resectability evaluations 
remains controversial. EUS is included as a routine imaging 
tool in the ESMO guidelines, but not in the NCCN guidelines. 
The primary goal of EUS is to perform pathologic diagnosis 
using fine-needle aspiration (FNA).
Histologic Diagnosis of Pancreatic Cancer
For patients with resectable disease, preoperative 
histologic confirmation is not mandatory, and resection 
Fig. 3. Detection of small liver metastasis in MRI. A 65-year-old male patient was admitted for chronic pancreatitis and pancreatic body 
cancer. 
Since there was no apparent vascular invasion in CT (A) and no demonstrable metastatic lesion in CT (B) and PET/CT (C), the pancreatic 
lesion was considered to be resectable. However, MRI showed multiple small hepatic lesions (white arrows) with peripheral enhancement in the 
pancreatic phase (D), hypointensity in the venous phase (E), decreased uptake in the hepatobiliary phase (F), hyperintensity in the T2-weighted 
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strongly recommended (17). Genetic profiling may require 
additional tissue sampling; however, it could provide 
clinically relevant information. Targeted DNA sequencing 
and analysis using biopsied tissue could be performed 
without delaying routine diagnostic workup for pancreatic 
cancer, which could identify potentially actionable targets 
in 17–26% of patients (60, 61).
Staging of Pancreatic Cancer
For pathologic staging, tumor-node-metastasis (TNM) 
staging developed by the American Joint Committee on 
Cancer is commonly used. Recently, TNM staging was 
updated to the 8th edition (62). In the 8th edition, T 
stage was changed to be based on the tumor size, and 
the extrapancreatic extension and resectable status were 
removed from the definition of T stage (Table 2). Regional 
lymph node metastasis was subdivided into N1 and N2, 
according to the number of metastatic lymph nodes. With 
the changed definitions of T and N stages, the 8th edition 
provides better reproducibility and improved prognostic 
accuracy compared to the 7th edition (63-66). Particularly, 
the newly introduced N2 stage is highly prognostic, 
emphasizing the importance of nodal staging (63, 64). 
The treatment strategy for pancreatic cancer is determined 
by the resectability status, and pathologic staging is only 
possible in resected pancreatic cancers; therefore, the 
clinical utility of pathologic TNM stage is limited. 
Resectability Evaluation
The resectability of pancreatic cancer plays a pivotal role 
in deciding the treatment strategy. Localized pancreatic 
cancers can be categorized as resectable pancreatic cancers 
that are candidates for upfront surgical resection, borderline 
resectable pancreatic cancers that could be candidates for 
surgical resection upon favorable response to neoadjuvant 
therapy, and locally advanced pancreas cancers in which 
surgical resection is difficult to attempt and chemotherapy 
and/or radiation therapy are preferred. Several resectability 
criteria have been proposed (Table 3), and they share key 
anatomic structures for determining resectability, including 
the celiac artery, common hepatic artery (CHA), superior 
mesenteric artery (SMA), superior mesenteric vein (SMV), 
and portal vein (PV) (6, 7, 14, 67). Detailed assessment 
of vascular contact or involvement should be performed, 
including abutment (tumor involvement of ≤ 180° of the 
vascular circumference), encasement (tumor involvement of 
> 180° of the vascular circumference), deformity, occlusion, 
and thrombosis (bland or tumor) (Fig. 4). 
The main difference between guidelines is related to the 
inclusion of surgical reconstructability of artery and vein 
in the determination of borderline resectability. For SMV/
PV, in all guidelines, surgically reconstructable involvement 
of pancreatic cancer was used as a criterion for borderline 
resectability. For CHA, the MD Anderson and Alliance for 
Clinical Trials in Oncology group criteria use surgically 
reconstructable involvement as a criterion for borderline 
resectability; however, the NCCN criteria use celiac axis 
or CHA-celiac bifurcation involvement as a criterion. For 
the celiac axis, surgically reconstructable involvement is a 
criterion for borderline resectability in MD Anderson criteria. 
In contrast, NCCN criteria describe the cases of borderline 
resectability in detail, according to tumor location. For 
SMA, all guidelines use the criteria for tumor abutment 
rather than surgical reconstructability in determining 
borderline resectability.
Although the definition of resectability is debatable, both 
the NCCN and ESMO guidelines currently recommend the 
use of NCCN resectability criteria, which is adapted from a 
consensus statement of the Society of Abdominal Radiology 
and the American Pancreatic Association (8, 68). When 
resectability was evaluated by NCCN guidelines, the R0 
resection rate in upfront surgery was reported to be 73%, 
55%, and 16% in resectable, borderline resectable, and 
locally advanced status, respectively (69).
The resectability of pancreatic cancer should be 
determined through a multidisciplinary consultation, ideally 
including diagnostic imaging, interventional endoscopy, 
medical oncology, radiation oncology, surgery, pathology, 
geriatric medicine, and palliative care (7). For proper 
communication among experts in various fields, the use of 
a structured reporting form is recommended for radiologic 
reporting (68).
In a meta-analysis performed in 2005, sensitivity and 
specificity of helical CT for resectability were 81% and 
82%, respectively, while those of MRI were 82% and 78%, 
respectively (32). A prospective study published in 2004 
also showed that helical CT has a superior diagnostic 
performance (sensitivity and specificity of 76% and 97%, 
respectively) compared to MRI (57% and 90%) and EUS 
(23% and 100%) (70). In these reports, most of the 
CTs were helical CT, not multidetector CT, with limited 
3D reformatting capability, and MRI showed low spatial 




Table 2. Pathologic Tumor-Node-Metastasis Staging System of the AJCC
T Category
AJCC 7th Edition AJCC 8th Edition
T Criteria T Criteria Changes in 8th Edition
TX Primary tumor cannot be assessed Primary tumor cannot be assessed
T0 No evidence of primary tumor No evidence of primary tumor
Tis
Carcinoma in situ, including PanIN with  
  high-grade dysplasia
Carcinoma in situ, including PanIN, IPMN,  
  ITPN, and MCN with high-grade dysplasia
IPMN, ITPN, and MCN with high 
   grade dysplasia were added to 
this category
T1
Tumor limited to the pancreas, 2 cm or  
  less in greatest dimension
Tumor ≤ 2 cm in greatest dimension
T1a: tumor ≤ 0.5 cm in greatest dimension
T1b:  tumor > 0.5 cm and < 1 cm in 
greatest dimension
T1c: tumor 1–2 cm in greatest dimension
T1 were subcategorized into  
   T1a, T1b, and T1c based on 
size
T2
Tumor limited to the pancreas, more than 
  2 cm in greatest dimension 
Tumor > 2 cm and ≤ 4 cm in greatest  
  dimension
Definitions of T2, T3 were  
  based on size
T3
Tumor extends beyond the pancreas, but  
   without involvement of the celiac axis 
or the SMA
Tumor > 4 cm in greatest dimension
Extrapancreatic extension was  
  removed from the criteria
T4
Tumor involves the celiac axis or the  
   SMA (unresectable primary tumor) 
Tumor involves celiac axis, SMA, and/or  
  CHA, regardless of size
Resectability was removed from 
  the definition
N Category N Criteria N Criteria
NX Regional lymph nodes cannot be assessed Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis No regional lymph node metastasis
N1 Regional lymph node metastasis
Metastasis in one to three regional lymph  
  nodes
Regional lymph node positivity  
   was divided to N1 and N2 
based on the number of 
metastatic lymph nodes
N2
Metastasis in four or more regional lymph  
  nodes
M Category M Criteria M Criteria 
M0 No distant metastasis No distant metastasis




0 Tis N0 M0 Tis N0 M0
IA T1 N0 M0 T1 N0 M0
IB T2 N0 M0 T2 N0 M0












T4 (any N) M0
T1–3 N2 M0 pancreatic cancers  
  were added to stage III
IV (Any T) (any N) M1 (Any T) (any N) M1
AJCC = American Joint Committee on Cancer, CHA = common hepatic artery, IPMN = intraductal papillary mucinous neoplasm, ITPN = 
intraductal tubulopapillary neoplasm, MCN = mucinous cystic noeplasm, PanIN = pancreatic intraepithelial neoplasia, SMA = superior 
mesenteric artery
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section thickness). More recently, several studies compared 
the diagnostic performance for resectability between 
multidetector CT and MRI with a 3D T1 sequence for dynamic 
phases. They showed similar diagnostic performance of 
multidetector CT (sensitivity and specificity of 87–88% and 
63–86%, respectively) and MRI (sensitivity and specificity 
of 83–93% and 50–75%, respectively). Although MRI shows 
similar diagnostic performance as that of CT, CT is preferred 
over MRI due to the limited availability and high cost of 
MRI.
A problem with resectability evaluations using the 
current imaging modalities is the debate in interobserver 
agreements. One study reported a very high interobserver 
agreement on NCCN criteria (71), while another study 
demonstrated low interobserver agreement even with 
experienced radiologists, particularly for borderline 
Table 3. Comparison of Resectability Criteria for Pancreatic Cancer without Distant Metastasis
Resectability Status
Resectability Criteria
MD Anderson (14) AHPBA/SSAT/SSO (6) Alliance (60) NCCN (7)
Celiac artery
Resectable No involvement No involvement No involvement No involvement
Borderline
Short-segment  




(Body/tail only) encasement (> 180°)  
   without aorta nor gastroduodenal artery, 
reconstructable with modified Appleby 
procedure
Locally advanced
Encasement and no  
   technical option for 
reconstruction
Any involvement Encasement (> 180°)
(Head/uncinate only) encasement  
  (> 180°)
(Body/tail only) encasement (> 180°),  
  surgically unreconstructable
CHA
Resectable No involvement No involvement No involvement No involvement
Borderline
Short-segment  
   abutment or 
encasement
Abutment (≤ 180°) or  
   gastroduodenal 
artery encasement up 
to hepatic artery
Any surgically  
   reconstructable 
involvement
Any involvement without celiac axis or  
  CHA bifurcation
Locally advanced
Encasement and no  




   unreconstructable 
involvement
Any involvement with celiac axis or CHA  
  bifurcation
SMA
Resectable No involvement No involvement No involvement No involvement
Borderline Abutment (≤ 180°) Abutment (≤ 180°) Abutment (≤ 180°) Abutment (≤ 180°)
Locally advanced Encasement (> 180°) Encasement (> 180°) Encasement (> 180°) Encasement (> 180°)
SMV/PV
Resectable Patent
No abutment,  
   distortion, tumor 
thrombus, or 
encasement
No involvement or  
  abutment (≤ 180°)
No involvement or abutment (≤ 180°),  
  without vein contour irregularity
Borderline
Short-segmental  
   occlusion and 
surgically 
reconstructable
Any surgically  
   reconstructable 
involvement
Any surgically  
   reconstructable 
involvement
Encasement (> 180°), or abutment  
   (≤ 180°) with venous contour 
irregularity or thrombosis, but surgically 
reconstructable
Locally advanced
Occluded and no  
   technical option for 
reconstruction
Surgically  
   unreconstructable 
involvement
Surgically  
   unreconstructable 
involvement
Surgically unreconstructable  
  involvement or occlusion 
AHPBA = American Hepato-Pancreato-Biliary Association, NCCN = National Comprehensive Cancer Network, PV = portal vein, SMV = 




becomes unresectable and the treatment strategy must be 
changed.
Radiologic evaluation of tumor regression is known to be 
more difficult than tumor progression in pancreatic cancer, 
especially after neoadjuvant therapy. Radiologic response 
does not accurately reflect pathological tumor regression 
(77). Neoadjuvant therapy induces necrosis, edema, 
inflammation, and fibrosis of the tumor, interfering with the 
radiologic evaluation of tumor regression (77, 78). Therefore, 
neoadjuvant therapy decreases the accuracy of CT scans in 
determining resectability. Overestimation of the remaining 
tumor size and vascular invasion is commonly known to occur 
(79). Thus, changes in tumor size are not well-associated 
with resectability after neoadjuvant therapy (80).
In a retrospective study, among 122 borderline resectable 
patients who underwent neoadjuvant therapy, only a small 
proportion demonstrated a radiologic complete response 
(0%) or partial response (12%), while the majority showed 
stable disease (69%). Radiologic downstaging from 
borderline resectable to resectable status was only observed 
in one (0.8%) patient. Despite the limited radiologic 
response, 66% (85/129) of the patients underwent surgical 
resection, and R0 resection was achieved in 95% (81/85) of 
patients who underwent surgery. Tumor response evaluated 
by the Response Evaluation Criteria In Solid Tumors (RECIST) 
1.1 was not associated with overall survival (81). Another 
study showed that the majority of patients who underwent 
neoadjuvant therapy and surgical resection continued to 
exhibit a locally advanced or borderline resectable stage 
resectable cases (72). 
Surveillance after Surgical Resection
The value of postoperative surveillance in pancreatic 
cancer is controversial. Although routine surveillance 
imaging studies would increase medical costs, there is no 
firm evidence of routine surveillance increasing survival 
rates (73-75). Although carbohydrate antigen 19-9 (CA19-9) 
is the most widely used serum biomarker for postoperative 
surveillance, CA19-9 surveillance lacks evidence for survival 
benefits (76). The ESMO guideline does not recommend 
routine imaging studies for postoperative surveillance. 
In contrast, the NCCN guideline recommends chest CT, 
abdominal and pelvic CT or MRI, and serum CA19-9 
examination every 3–6 months for 2 years after surgery and 
then every 6–12 months.
Unsolved or Debated Issues Related to Imaging 
in Pancreatic Cancer
Resectability Evaluation in Patients Receiving 
Neoadjuvant Treatment 
When evaluating images of patients undergoing 
chemotherapy or chemoradiation with the aim of 
neoadjuvant therapy, the radiologist should evaluate both 
the progression and regression of the disease. Assessment 
of an increasing tumor extent or newly occurring metastatic 
lesions is important, as the lesion in such cases often 
Fig. 4. Resectability of pancreatic cancer determined by the National Comprehensive Cancer Network criteria.
A. Approximately 2-cm resectable pancreatic cancer (white arrow) confined to the pancreas showing no vascular involvement.  
B. Approximately 2.5-cm borderline resectable pancreatic cancer (white arrowhead) exhibiting superior mesenteric artery contact of less 
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(70%) on CT. However, R0 resection was possible in 92% of 
cases (82). 
To overcome the limitations of radiologic response 
evaluation, several alternative assessment methods have 
been investigated (83-85). A recent prospective study 
suggested that partial regression of tumor contact with 
vascular structures on pancreatic CT indicates a high 
likelihood of R0 resection and suitability for surgical 
exploration (86). A perivascular halo in post-neoadjuvant 
therapy CT could also be a sign of regression of tumor-
vascular contact and the possibility of R0 resection 
(87). Increased tumor attenuation in the pancreatic and 
venous phases of post-neoadjuvant CT, compared to pre-
neoadjuvant CT, was most likely attributed to increased 
fibrosis and was associated with R0 resection (88). 
However, changes in tumor attenuation require prospective 
validation, as other studies have shown contradictory 
results (86, 89).
Recent studies have indicated that quantitative radiomic 
analysis is promising for predicting histologic tumor 
response. In patients with appropriate histologic response 
to chemoradiation, a decreased mean CT number, skewness, 
and increased kurtosis have been observed in posttreatment 
unenhanced CT (90). 
Perfusion or diffusion parameters could also be used to 
predict resectability after neoadjuvant treatment. A high 
value of the volume transfer constant in pretreatment CT 
or MRI was significantly correlated with radiologic tumor 
response (91, 92). Preoperative or postoperative apparent 
diffusion coefficient (ADC) values were significantly 
associated with R0 resection (93, 94). An increased ADC 
in post-chemoradiation MRI compared to that in pre-
chemoradiation MRI was associated with a histopathological 
response of pancreatic cancer, suggesting that ADC is a 
potential biomarker for pathological response (94). A small 
prospective study showed an association between the 
metabolic response in PET/CT (≥ 30% decreased 18FDG uptake 
after neoadjuvant therapy) and histologic tumor regression 
(95). Another study also showed that better pathologic 
response is expected in a metabolic responder (pretreatment 
standardized uptake value [SUV] ≥ 4.7 and ≥ 46% decreased 
18FDG uptake after neoadjuvant therapy) (96). 
These novel imaging parameters, including radiomics, 
perfusion, diffusion, and metabolic imaging, demonstrate 
promising results; however, there is limited evidence for 
predicting R0 resection before surgical resection.
Response Evaluation in Locally Advanced Pancreatic 
Cancer
In patients with unresectable disease, the World Health 
Organization (WHO) guidelines or RECIST version 1.0 or 1.1 
are widely used for evaluation of response to chemotherapy 
and/or chemoradiation. In recent phase III clinical trials 
comparing combined chemotherapy regimens (FOLFIRINOX 
or gemcitabine + nab-paclitaxel) and gemcitabine 
monotherapy, RECIST 1.0 was used for response assessment 
(97, 98). In these studies, progression-free survival 
increased along with the overall survival in the combined 
chemotherapy group, suggesting that progression defined 
by RECIST 1.0 has clinical relevance. However, evaluation 
of imaging response in unresectable disease is associated 
with the same problems as those encountered in cases 
undergoing neoadjuvant therapy, including difficulties in 
size measurement in infiltrative or irregular tumors as well 
as inaccuracies in the assessment of tumor regression (Fig. 
5). In a consensus statement from the National Cancer 
Institute clinical trials planning meeting on pancreatic 
cancer treatment, tumor shrinkage assessed by either WHO 
or RECIST was not recommended as a primary endpoint 
of clinical trials, as they are poor surrogates for overall 
survival (99).
In the nab-paclitaxel + gemcitabine phase III trial, 
metabolic response defined by decreased SUV on 18FDG-PET/
CT was more frequently observed than radiologic response, 
and metabolic response was associated with longer overall 
survival (100).
Predicting Prognosis in Patients with Upfront Surgery 
According to the current guidelines, resectable pancreatic 
cancers are recommended for upfront surgery (5, 7, 18). 
However, resectable pancreatic cancers with high-risk 
features, such as high serum CA19-9 levels, large primary 
tumors, large regional lymph nodes, as well as excessive 
weight loss and extreme pain, could also be candidates for 
neoadjuvant therapy (7). Recently, the role of neoadjuvant 
strategy has been gradually increasing. In a recent 
meta-analysis, surgery after neoadjuvant therapy was 
reported to improve overall survival compared to adjuvant 
chemotherapy after upfront surgery (101). To date, no large-
scale phase III trial has been published; however, small 
prospective trials showed better survival using neoadjuvant 
strategies (102). If we could perform preoperative survival 
stratification of the candidates for upfront surgery, patients 




enhancing areas of pancreatic cancer correspond to necrotic 
or fibrotic areas, which contribute to the aggressive nature 
of the disease (108).
DWI is another imaging method that reflects the fibrotic 
stromal component of pancreatic cancer (109, 110). 
However, the prognostic significance of ADC is variable; 
some studies showed strong association between low ADC 
values and poor overall survival, while others demonstrated 
no significant association (103, 111-113). Recently, the 
low ADC value of the upstream pancreas was reported to be 
significantly associated with overall survival after curative 
resection, suggesting an association between inflammation 
and pancreatic cancer progression (111).
18FDG-PET/CT can also be used to predict the postsurgical 
outcome of pancreatic cancer. Several studies have reported 
neoadjuvant strategies. Imaging studies are expected to 
play an important role in the survival stratification and 
assessment of resectability. However, only a limited number 
of studies are being performed on the imaging prognostic 
biomarker.
Pancreatic cancers with irregular rim-like enhancement 
and a relatively hypovascular central area on dynamic MRI 
showed poor differentiation and frequent tumor necrosis, 
as well as poorer disease-free survival and overall survival 
(103). Similarly, several studies demonstrated that lower 
enhancement of pancreatic cancer in the venous phase of 
CT was associated with poor overall survival (104-106). A 
CT texture analysis revealed that low average attenuation 
and standard deviation in the pancreatic phase image was 
associated with poor disease-free survival (107). Poorly 
Fig. 5. Pancreatic cancer showing partial response after a long period of chemotherapy. A 55-year-old female was diagnosed with 
pancreatic cancer in the uncinate process. 
A, B. The pancreatic phase of initial CT showed an infiltrative hypoenhancing mass lesion (white arrows) involving the uncinate process and 
retroperitoneal margin, as well as encasing superior mesenteric artery (white arrowheads) and its jejunal branches, suggesting locally advanced 
tumor. C, D. After approximately 2 years of FOLFIRINOX chemotherapy, the lesion (black arrows) showed a reduction in size and extent of vascular 
involvement. It was apparent that the tumor became smaller with chemotherapy, but it was difficult to determine exactly how much of the viable 
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that the metabolic tumor volume, total lesion glycolysis, or 
maximum SUV (SUVmax) were associated with disease-free 
survival or overall survival. In particular, pancreatic cancers 
with high SUVmax values showed consistently poor overall 
survival, although the cutoff point was different among 
studies (114-117).
Summary
In pancreatic cancer, imaging plays an essential role in 
the surveillance, diagnosis, resectability evaluation, and 
response evaluation. With the development of therapeutic 
strategies for pancreatic cancer, the role of imaging has 
been gradually changing. Surveillance of pancreatic cancer 
should be performed only in high-risk individuals, and 
MRI and EUS are the preferred imaging modalities. CT is 
primarily used for imaging diagnosis and resectability 
evaluation of pancreatic cancers, and MRI, PET-CT, and EUS 
could be optionally used at the radiologist’s discretion. It is 
not accurate to evaluate the regression of pancreatic cancer 
in imaging after chemotherapy or chemoradiation therapy, 
and tumor shrinkage in imaging is a poor surrogate for 
overall survival of pancreatic cancer. Although innovative 
evaluation methods using new radiologic criteria (i.e., 
perfusion imaging, radiomics, DWI, PET/CT, etc.) have been 
proposed, there is insufficient evidence for their clinical 
usefulness. Post-surgical outcome prediction in resectable 
pancreatic cancers, treatment response evaluation, and 
prognosis prediction of unresectable pancreatic cancers are 
problems that remain unsolved. 
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